TroxBio Wants Its Medical Claims Tested the Hard Way

Field notes

TroxBio groups one founder-developed botanical programme with two devices sourced from independent engineering teams. The public page says all three remain untested at the scale needed to settle their claims, while the company proposes independent, preregistered studies whose results would be published whether favorable or negative. One device targets screening outside a hospital setting; the other is described as addressing a chronic disease mechanism rather than managing symptoms. Supporting technical material is withheld from the public site under confidentiality.